Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:29 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
S1300: Pemetrexed Disodium With or Without Crizotinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer That Has Progressed After Crizotinib
NCT02134912 · SWOG Cancer Research Network · PHASE2 · terminated · last registry update 2020-02-20 · Non-small cell lung cancer · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “science has moved forward and there is no intent to complete the study” | Open Targets' class: business administrative | Registry record, SWOG Cancer Research Network |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against MET in non-small cell lung cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2020-11-17Phase 3 first posted: Qilu Pharmaceutical Co., Ltd., WX-0593 Tablets + crizotinib (NCT04632758)
- 2020-10-27Phase 3 first posted: Hoffmann-La Roche, Entrectinib + Crizotinib (NCT04603807)
- 2020-09-04Phase 3 first posted: Janssen Research & Development, LLC, Amivantamab + Pemetrexed (NCT04538664)
- 2020-07-27Phase 3 first posted: Janssen Research & Development, LLC, Amivantamab + Osimertinib (NCT04487080)
- 2020-07-15Phase 3 first posted: Hoffmann-La Roche, Cabozantinib + Atezolizumab (NCT04471428)
- 2020-06-11Phase 3 first posted: Novartis Pharmaceuticals, Capmatinib + Docetaxel (NCT04427072)
- 2019-07-11Results posted on the registry: Hoffmann-La Roche, Alectinib + Crizotinib (NCT02838420)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision